Investors bought shares of Agilent Technologies Inc (NYSE:A) on weakness during trading on Monday. $61.41 million flowed into the stock on the tick-up and $24.91 million flowed out of the stock on the tick-down, for a money net flow of $36.50 million into the stock. Of all companies tracked, Agilent Technologies had the 16th highest net in-flow for the day. Agilent Technologies traded down ($0.05) for the day and closed at $71.97
A has been the topic of a number of research analyst reports. Robert W. Baird restated a “buy” rating and set a $76.00 price objective on shares of Agilent Technologies in a research report on Thursday, January 18th. Barclays restated a “buy” rating and set a $74.00 price objective on shares of Agilent Technologies in a research report on Monday, January 8th. Deutsche Bank set a $75.00 price objective on shares of Agilent Technologies and gave the company a “buy” rating in a research report on Tuesday, November 21st. Zacks Investment Research upgraded shares of Agilent Technologies from a “hold” rating to a “buy” rating and set a $76.00 price objective on the stock in a research report on Tuesday, October 31st. Finally, Cowen restated a “hold” rating and set a $70.00 price objective on shares of Agilent Technologies in a research report on Wednesday, November 22nd. Five equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Agilent Technologies presently has a consensus rating of “Buy” and a consensus price target of $70.98.
The company has a market capitalization of $22,960.00, a price-to-earnings ratio of 31.73, a P/E/G ratio of 2.41 and a beta of 1.28. The company has a debt-to-equity ratio of 0.40, a quick ratio of 2.78 and a current ratio of 3.23.
In other news, CEO Michael R. Mcmullen sold 21,850 shares of the stock in a transaction on Monday, January 29th. The shares were sold at an average price of $75.00, for a total value of $1,638,750.00. Following the completion of the sale, the chief executive officer now directly owns 324,687 shares of the company’s stock, valued at $24,351,525. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Didier Hirsch sold 20,000 shares of the stock in a transaction on Monday, November 27th. The stock was sold at an average price of $69.40, for a total transaction of $1,388,000.00. Following the completion of the sale, the chief financial officer now directly owns 204,851 shares of the company’s stock, valued at $14,216,659.40. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 154,707 shares of company stock valued at $10,944,828.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Dupont Capital Management Corp purchased a new stake in shares of Agilent Technologies in the third quarter worth $101,000. Front Row Advisors LLC purchased a new stake in shares of Agilent Technologies in the fourth quarter worth $106,000. Compagnie Lombard Odier SCmA purchased a new stake in shares of Agilent Technologies in the fourth quarter worth $126,000. AMG National Trust Bank purchased a new position in Agilent Technologies during the fourth quarter valued at $201,000. Finally, Premia Global Advisors LLC purchased a new position in Agilent Technologies during the fourth quarter valued at $204,000.
TRADEMARK VIOLATION NOTICE: This story was first published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this story on another site, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark laws. The original version of this story can be read at https://stocknewstimes.com/2018/02/21/traders-buy-shares-of-agilent-technologies-a-on-weakness-2.html.
About Agilent Technologies
Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.